J-Brain Cargo®, which is a JCR proprietary technology, allows the delivery of biotherapeutics into the central nervous system (“CNS”) via a...
Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body's immune ...
The Patent No. US 11,602,282 B2 describes how the signals recorded from Nox standard respiratory effort bands (RIP) can be used to derive information on in...
Histogen Inc. (HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-casp...
Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced new data, covered by its previously filed patents, demonstrati...
In 2017, Sanofi/Regeneron announced the FDA approval for the first biologic agent to treat atopic dermatitis (AD). The success of that drug, Dupixent (dupi...
Lack of access to qualified health personnel combined with an alarming prevalence of noncommunicable diseases (NCDs) such as cardiometabolic diseases (CMDs...
If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to ...
Medtronic plc (NYSE: MDT) and DaVita Inc. (NYSE: DVA) announced the launch of Mozarc Medical—an independent new company committed to reshap...
The Problem with EzriCare EyedropsWhen you use eyedrops or any other eye product, you trust the product to help, and not hurt, your eye health. But the pri...
The gold standard clinical assessment of treatment response is to measure changes in tumor volume over time. Typically, the RECIST (Response Evaluation Cri...
More recently, the CRISPR system has been used to edit human induced pluripotent stem cells (iPSCs), which are known to exhibit phenotypes closer to human ...
Coloplast has finalised its first pivotal clinical study on Luja, a new intermittent male catheter, designed to reduce the risk of urinary tract infections...
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assay...
© 2025 Biopharma Boardroom. All Rights Reserved.
